My Account
Log in Registration
All
Cart
Highlights
Fiction Books
Non-Fiction Books
Children's Books
Rare Books
Music
DVD & Blu-Ray
Video Games
Category
Wishlists
Cart
All
Free Shipping in Australia
Trustpilot
Proud to be B-Corp

Pancreatic Cancer: Basic Mechanisms and Therapies Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)

Pancreatic Cancer: Basic Mechanisms and Therapies By Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)

Pancreatic Cancer: Basic Mechanisms and Therapies by Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)

Reviews:
$297.89
Condition - New
Only 2 left
New

Pancreatic Cancer: Basic Mechanisms and Therapies Summary

Pancreatic Cancer: Basic Mechanisms and Therapies: Volume 159 by Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)

Pancreatic Cancer: Basic Mechanisms and Therapies, Volume 159 in the Advances in Cancer Research, presents the latest release in this ongoing, well-regarded serial with invaluable information on the exciting and fast-moving field of cancer research. Pancreatic cancer (PC) is the third leading cause of cancer-related deaths in the United States. Greater than 90% PCs are Pancreatic ductal adenocarcinomas (PDAC) which have a dismal estimated 5-year overall survival of only 11%. PDAC is predicted to become the second leading cause of mortality in the United States by 2030. In the clinic, the PDAC patients often present with incurable disease at the time of first diagnosis. This cancer is particularly lethal because of its propensity to spread quickly to distant organs including the lymphatic system. PDAC metastasis occurs shortly after tumor initiation and is caused by a complex interaction between autonomous tumor cells and cellular elements of the tumor microenvironment. Although PDAC remains a challenging disease to treat and a leading cause of cancer-related deaths, progress is being made in disease etiology and pathogenesis, and intensive research is focused on developing optimal treatment approaches for patients. Considering the continuous progress being made in understanding PDAC pathogenesis and designing new therapies, it was considered timely to develop an up-to-date thematic issue of Advances in Cancer Research (ACR) focused on PDAC. In this thematic issue, we have included ten review articles by experts that cover cancer disparities, PDAC pathobiology, the roles of the tumor microenvironment, tumor heterogeneity, PC stem cells, genetic and signaling events critical for PDAC pathogenesis, Immunotherapy and chemoresistance in PDAC, and different PDAC mouse models. This special issue highlights recent research progress in PDAC, which bridges the gap between basic and clinical research.

About Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)

Luni Emdad, PhD, MBBS received her PhD degree in Medical Science from the Nagoya University Graduate School of Medicine and her Bachelor degree in Medicine and Surgery (MBBS) from Dhaka Medical college. After completing her Postdoctoral training in the department of Pathology and Urology with Dr. Paul B. Fisher at the Columbia University, she remained as Associate Research Scientist at the Columbia University until Dec 2007. From 2008-2011, she served as Assistant Professor, Department of Neurosurgery, Mount Sinai School of Medicine, New York. In 2011, she joined the Department of Human and Molecular Genetics, Virginia Commonwealth University as an Assistant professor. In 2020, she was promoted to Associate professor at Virginia Commonwealth University. Dr. Emdad is a scientist with a clinical background (dual degree of Bachelors of Medicine and Surgery and Ph.D.) and has a longstanding research experience in cancer research with in depth molecular knowledge in targeted experimental therapeutics development for cancer. She has published over 150 in journals such as Proceedings of the National Academy of Science USA, Cancer Research, Journal of Clinical Investigation, Hepatology, Oncogene, Semin Cancer Biol, Neuro-Oncology and so on. She has served as principal investigator in two sponsored research programs and an inventor in two issued US patents. Dr. Azeddine Atfi is the leader of Cancer Biology Program at NCI-designated Massey Cancer Center. He is also the Professor and Chair of the Cellular and Molecular Pathogenesis Division at the Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA. Dr. Rajan Gogna is an assistant professor at the School of Medicine Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA. Dr. Jose Trevino is an associate professor at the Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (theranostics) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Table of Contents

1. Notch signaling pathway in pancreatic tumorigenesis Keli Xu 2. EMT in Pancreatic Ductal Adenocarcinoma Azeddine Atfi 3. Review of Immunocompetent In-vivo Models of PDAC OR Stromal Microenvironment Impact on Pacreatic Cancer Progression and Metastasis Vignesh Vudatha and Jose Trevino 4. Interplay between MAP Kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer Ajay Rana and Kumar Sandeep 5. KRAS in pancreatic cancer: Emerging therapeutic strategies Daohong Zhou 6. Disparities in Pancreatic Cancer Clinical Trials Allison Neal Martin and Rebecca A. Snyder 7. Tumor heterogeneity: an oncogenic driver of PDAC progression and therapy resistance under stress conditions Esha Madan 8. Oncogenic Signaling Pathways in Pancreatic Ductal Adenocarcinoma Kedar Nath Natarajan 9. Chemoresistance in Pancreatic Ductal Adenocarcinoma: Overcoming Resistance to Therapy Praveen Bhoopathi 10. Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma Rajan Gogna

Additional information

NGR9780443133541
9780443133541
0443133549
Pancreatic Cancer: Basic Mechanisms and Therapies: Volume 159 by Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)
Volume editor Luni Emdad (Associate Professor of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA)
New
Hardback
Elsevier Science Publishing Co Inc
2023-06-01
390
N/A
Book picture is for illustrative purposes only, actual binding, cover or edition may vary.
This is a new book - be the first to read this copy. With untouched pages and a perfect binding, your brand new copy is ready to be opened for the first time

Customer Reviews - Pancreatic Cancer: Basic Mechanisms and Therapies